Nucleic Acid Therapeutics, volume 32, issue 1, pages 14-28
CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers
Kostyushev Dmitry
1, 2
,
Ponomareva Natalia
1, 2, 3
,
Brezgin Sergey
1, 2
,
Chulanov Vladimir
1, 2, 3
1
National Medical Research Center of Tuberculosis and Infectious Diseases, Ministry of Health, Moscow, Russia.
|
Publication type: Journal Article
Publication date: 2022-02-01
Journal:
Nucleic Acid Therapeutics
Quartile SCImago
Q1
Quartile WOS
Q2
Impact factor: 4
ISSN: 21593337, 21593345
Drug Discovery
Biochemistry
Molecular Biology
Genetics
Molecular Medicine
Abstract
After almost a decade of using CRISPR/Cas9 systems to edit target genes, CRISPR/Cas9 and related technologies are rapidly moving to clinical trials. Hepatitis B virus (HBV), which causes severe liver disease, cannot be cleared by modern antivirals, but represents an ideal target for CRISPR/Cas9 systems. Early studies demonstrated very high antiviral potency of CRISPR/Cas9 and supported its use for developing a cure against chronic HBV infection. This review discusses the key issues that must be solved to make CRISPR/Cas9 an anti-HBV therapy.
Citations by journals
|
1
2
|
|
|
Molecular Biology
|
Molecular Biology
2 publications, 50%
|
|
Molecular Therapy - Nucleic Acids
|
Molecular Therapy - Nucleic Acids
2 publications, 50%
|
|
1
2
|
Citations by publishers
|
1
2
|
|
|
Pleiades Publishing
|
Pleiades Publishing
2 publications, 50%
|
|
Elsevier
|
Elsevier
2 publications, 50%
|
|
1
2
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2022,2023],"ids":[0,0],"codes":[0,0],"imageUrls":["",""],"datasets":[{"label":"Citations number","data":[2,2],"backgroundColor":["#3B82F6","#3B82F6"],"percentage":["50","50"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Molecular Biology","Molecular Therapy - Nucleic Acids"],"ids":[1134,20403],"codes":[0,0],"imageUrls":["\/storage\/images\/resized\/oZgeErrVFhuDksyqFURLvYS1wtVSBWczh001igGo_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp"],"datasets":[{"label":"","data":[2,2],"backgroundColor":["#3B82F6","#3B82F6"],"percentage":[50,50],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Pleiades Publishing","Elsevier"],"ids":[101,17],"codes":[0,0],"imageUrls":["\/storage\/images\/resized\/oZgeErrVFhuDksyqFURLvYS1wtVSBWczh001igGo_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp"],"datasets":[{"label":"","data":[2,2],"backgroundColor":["#3B82F6","#3B82F6"],"percentage":[50,50],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Metrics
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Kostyushev D. et al. CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers // Nucleic Acid Therapeutics. 2022. Vol. 32. No. 1. pp. 14-28.
GOST all authors (up to 50)
Copy
Kostyushev D., Kostyusheva A., Ponomareva N., Brezgin S., Chulanov V. CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers // Nucleic Acid Therapeutics. 2022. Vol. 32. No. 1. pp. 14-28.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1089/nat.2021.0075
UR - https://doi.org/10.1089%2Fnat.2021.0075
TI - CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers
T2 - Nucleic Acid Therapeutics
AU - Kostyushev, Dmitry
AU - Kostyusheva, Anastasiya
AU - Ponomareva, Natalia
AU - Brezgin, Sergey
AU - Chulanov, Vladimir
PY - 2022
DA - 2022/02/01 00:00:00
PB - Mary Ann Liebert
SP - 14-28
IS - 1
VL - 32
SN - 2159-3337
SN - 2159-3345
ER -
Cite this
BibTex
Copy
@article{2022_Kostyushev,
author = {Dmitry Kostyushev and Anastasiya Kostyusheva and Natalia Ponomareva and Sergey Brezgin and Vladimir Chulanov},
title = {CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers},
journal = {Nucleic Acid Therapeutics},
year = {2022},
volume = {32},
publisher = {Mary Ann Liebert},
month = {feb},
url = {https://doi.org/10.1089%2Fnat.2021.0075},
number = {1},
pages = {14--28},
doi = {10.1089/nat.2021.0075}
}
Cite this
MLA
Copy
Kostyushev, Dmitry, et al. “CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers.” Nucleic Acid Therapeutics, vol. 32, no. 1, Feb. 2022, pp. 14-28. https://doi.org/10.1089%2Fnat.2021.0075.